Tweets
RheumIQ: True or False: Severe allergic reactions to allopurinol are more common in patients with chronic kidney disease than in the general population.
See if you got it right at https://t.co/LATb1P18Sh. https://t.co/dFdrhso1oU
Dr. John Cush @RheumNow ( View Tweet )
1 hour 34 minutes ago
Persistence of education and monitoring is crucial to optimal gout management
Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the ACR gout management recommendations. It is important that the misconceptions and myths held https://t.co/XYSwvuihjJ
Dr. John Cush @RheumNow ( View Tweet )
3 hours 34 minutes ago
Patients with anemia (10% of the population) have a 2-fold increased risk of gout.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/lQoiFjubZJ, https://t.co/s8HeS9sbu0
Dr. John Cush @RheumNow ( View Tweet )
5 hours 33 minutes ago
Expert Perspective on Calcium Pyrophosphate Deposition Disease
A current perspective article by Dr. Sara Tedeschi tackles many unresolved issues around CPPD diagnosis, classification, and management, including the lack of clinical trials or FDA approved treatments. https://t.co/zxJ9aQweNl
Dr. John Cush @RheumNow ( View Tweet )
7 hours 34 minutes ago
Pragmatism in Gout: How therapeutic choices can have multiple benefits
William James famously wrote in Pragmatism, “There can be no difference anywhere that doesn’t make a difference elsewhere.” Gout treatment offers a striking medical example of that idea. https://t.co/DG29pro6XE
Dr. John Cush @RheumNow ( View Tweet )
21 hours 34 minutes ago
Gout and its' associated comorbidities - treat gout and its' comorbidities to target
https://t.co/U0dolcAGEc https://t.co/mGvYQrWx25
Dr. John Cush @RheumNow ( View Tweet )
23 hours 4 minutes ago
Among 784,091 pts in a UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities https://t.co/78oHVWTdTJ
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Nerandomilast (Jascayd) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug was approved for IPF & PPF by the FDA for US use in late 2025 https://t.co/scOuVb3aYy https://t.co/EcmpRhyWgu
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Coding: ICD-10 Code M45.7 describes ankylosing spondylitis of the lumbosacral region, a billable ICD-10-CM diagnosis code valid for FY2026. M45.7 became effective October 1, 2025 and belongs to the M45 parent category covering ankylosing spondylitis by anatomical site. https://t.co/jBmoD0CVps
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Chinese cohort of 209 AOSD pts identifed 49 (23%) w/ lung dz (by CXR), yet 69% were asymptomatic. Significcant risk factors for AOSD-LD were pleuritis, MAS (HR 2.62), & Dz relapse (HR 2.6). Imaging patterns: acute exudative pattern most prevalent, followed by interstitial and https://t.co/2IPJWRJicP
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
The Hidden Cost of Gout
For many people, gout is viewed as an episodic disease: a painful flare, a short course of treatment, and then life returns to normal. However, as rheumatologists, we know that recurrent attacks can lead to joint damage and tophi if left untreated. https://t.co/RWTp5KKkyw
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Fibromyalgia: Diagnosis and Management
https://t.co/L9nA1TlJKx https://t.co/G4bkxTsXCt
Dr. John Cush @RheumNow ( View Tweet )
1 day ago


